SHAREHOLDER ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Vistagen Therapeutics

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Vistagen Therapeutics, Inc. due to allegations of violations of federal securities laws related to misleading statements about its Phase 3 PALISADE-3 trial of fasedienol for social anxiety disorder [2][5]. Group 1: Company Overview - Vistagen Therapeutics, Inc. is a company listed on NASDAQ under the ticker VTGN [2]. - The company is developing fasedienol, an investigational pherine candidate aimed at treating social anxiety disorder [5]. Group 2: Legal Investigation and Claims - The law firm is encouraging investors who purchased Vistagen securities between April 1, 2024, and December 16, 2025, to discuss their legal rights [1]. - A federal securities class action has been filed against Vistagen, with a deadline of March 16, 2026, for investors to seek the role of lead plaintiff [2][7]. Group 3: Trial Results and Market Impact - On December 17, 2025, Vistagen announced that its PALISADE-3 study did not meet its primary efficacy endpoint, resulting in a significant stock price drop of $3.50, or 80.27%, closing at $0.86 [6].